Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CASP8
REST API REST API
Homo sapiens
CASP8 is differentially expressed in 319 experiments: 135 organism parts: bone marrow, brain, ... (133 more);, 231 disease states: normal, Huntington's disease, ... (229 more);, 102 cell types 424 cell lines 42 compound treatments and 72 other conditions.
Synonyms Casp-8, FLICE, MACH, MCH5
Orthologs Casp8 (Mus musculus)   Dcp-1 (Drosophila melanogaster)   Q2LGB8_BOVIN (Bos taurus)   decay (Drosophila melanogaster)   casp8 (Danio rerio)   casp8l1 (Danio rerio)   Ice (Drosophila melanogaster)   F7BL88_CIOIN (Ciona intestinalis)   F1NXP6_CHICK (Gallus gallus)   Casp8 (Rattus norvegicus)   Q38JA9_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, cytosol, response to antibiotic, protein binding, apoptosis, cytoskeleton, cytoplasm, innate immune response, protein complex, tumor necrosis factor receptor binding, peptidase activity, metabolic process, activation of caspase activity, membrane raft, mitochondrial outer membrane, identical protein binding, neuron projection, centrosome, cysteine-type endopeptidase activity, nucleus, heart development, response to lipopolysaccharide, proteolysis, proteolysis involved in cellular protein catabolic process, response to cold, response to ethanol, cysteine-type peptidase activity, mitochondrion, regulation of apoptosis, positive regulation of I-kappaB kinase/NF-kappaB cascade, neural tube formation, activation of pro-apoptotic gene products, cellular response to mechanical stimulus, response to tumor necrosis factor, activation of innate immune response, induction of apoptosis by intracellular signals, death-inducing signaling complex, response to cobalt ion, response to estradiol stimulus, induction of apoptosis by extracellular signals, Noc1p-Noc2p complex, macrophage differentiation, protein heterooligomerization, cellular component disassembly involved in apoptosis, CD95 death-inducing signaling complex, cell body, nucleotide-binding oligomerization domain containing signaling pathway
InterPro Term Pept_C14_p10, Pept_C14_ICE_p20, Pept_C14_p45_core, Pept_C14_cat, DED
UniProt Accession A8MU92, C9JB29, C3S3G0, Q14790, E7EQ06, E7EQ01, E7ETB7, E7EVN1, F8WF39
Gene-Disease Assocation CASPASE 8 DEFICIENCY, HEPATOCELLULAR CARCINOMA, LUNG CANCER, BREAST CANCER
Search EB-eye ENSG00000064012
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
PC3
3
E-GEOD-14464, E-GEOD-5258, E-MEXP-2034
A549
2
E-GEOD-3202, E-GEOD-6013
BT20
2
E-MTAB-37, E-MTAB-62
BT474
2
E-MEXP-440, E-MTAB-37
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
418 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
embryonic stem cell
2
E-GEOD-2248, E-MEXP-930
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-145, E-TABM-130
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (72 experiments)

Factor Value U/D Experiments
Huntington's disease
3
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-5550
225 more value(s).


Compound treatment

studied in E-GEOD-5542, E-GEOD-3720, E-TABM-868, E-MEXP-1958, E-MEXP-941, ... (27 experiments)

Factor Value U/D Experiments
none
2
9
E-GEOD-412, E-TABM-868, E-GEOD-5542, E-MEXP-1958, E-GEOD-2322, ... (11 experiments)
control
2
E-GEOD-3284, E-GEOD-4006
lipopolysaccharide
1
2
E-TABM-868, E-MEXP-1958, E-GEOD-3720
unknown
1
E-GEOD-7307
nocodazole
1
E-GEOD-571
control - interferon-gamma
1
E-GEOD-7216
36 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-GEOD-18736, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-1956, ... (44 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922, E-TABM-147

Processing time: 0.473 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM